| Covariate | Person 1 High consideration for cost and CVD (weight of 1) Without normalized disability weight |
Person1 High consideration for cost and CVD (weight of 1) With normalized disability weight |
|---|---|---|
| Sex | Male | Male |
| Age | 63 | 63 |
| Race | Hispanic | Hispanic |
| SBP (mmHg) | 134.7 | 134.7 |
| Statin use | No | No |
| Anticoagulant use | No | No |
| BP medication use | Yes | Yes |
| Currently smoking | No | No |
| Oral diabetes medication use | Yes | Yes |
| Total cholesterol (mg/dL) | 181 (4.8 mmol/L) | 181 (4.8 mmol/L) |
| HDL cholesterol (mg/dL) | 61 (1.4 mmol/L) | 61 (1.4 mmol/L) |
| Hemoglobin A1c (%) | 6.1 (51.5 mmol/mol) | 6.1 (51.5 mmol/mol) |
| Serum creatinine (mg/DL) | 0.63 (53.0 μmol/L) | 0.63 (53.0 μmol/L) |
| Urine albumin creatinine ratio (mg/g) | 301.6 | 301.6 |
| CVD history | No | No |
| CVD risk (10-yr risk, %) | ||
| Myocardial infarction | 4 | 4 |
| Stroke | 1 | 1 |
| Microvascular risk (10-yr risk, %) | ||
| Nephropathy | 5 | 5 |
| Retinopathy | 6 | 6 |
| Neuropathy | 6 | 6 |
| Drug ranking score (95% CI) based on network meta-analysis12* | ||
| 1st | SU 1.0 [0.71,1.28] |
SGLT-2-i 1.0 [0.77, 1.23] |
| 2nd | TZD 0.90 [0.56, 1.27] |
SU 0.81 [0.37, 1.25] |
| 3rd | SGLT-2-i 0.87 [0.72,1.02] |
TZD 0.79 [0.41,1.18] |
| 4th | Basal insulin 0.81 [0.31, 1.29] |
GLP-1 0.78 [0.73, 1.26] |
| 5th | DPP-4 0.77 [0.45, 1.02] |
Basal insulin 0.78 [0.16, 1.37] |
| 6th | GLP-1 0.62 [0.26, 0.99] |
DPP-4 0.77 [0.36, 1.17] |
*
Drug ranking scores were normalized by the best ranking score. Score of 1 refers to the best ranking score, and the scores for other drugs are ranking scores relative the best ranking score. 95% confidence intervals were generated based on the uncertainty around the treatment effect estimates from the network meta-analysis.
TZD: Thiazolidinedione; SU: Sulfonylurea; GLP-1RA; GLP-1 agonist; SGLT-2-I; SGLT-2 inhibitor; DPP-4-I; DPP-4 inhibitor